OQRO

Weekly recap

Insider trades and Congress trades, week of Jul 20–26, 2026

In the week of Jul 20–26, 2026, insiders filed 84 open-market purchases worth about $46.8M and 406 open-market sales; the largest purchase was $12.4M of Crescent Biopharma (CBIO) by Fairmount Funds Management LLC; members of Congress disclosed 277 purchases and 51 sales; 10 purchases stood out against the company's record since 2006.

By filing date, Monday to Sunday. Every line links to its SEC, House or Senate record. Public filings, not investment advice.

Purchases that stand out against 20 years of filings

Measured against every open-market trade the company's insiders filed since 2006. See all of them on the rare insider trades page.

Largest insider purchases

Largest insider sales

Congress trades disclosed

Members report a value range, not an exact amount; the trade can be up to 45 days older than its report.

Executives who announced they are leaving

  • Credit Acceptance (CACC) · Jul 24, 2026

    “On July 20, 2026, the Board of Directors of Credit Acceptance Corporation (referred to as the “Company,” “Credit Acceptance,” “we,” “our” or “us”) and Ravi Mohan, the Company’s Chief Technology Officer, mutually agreed that Mr. Mohan would resign as Chief Technology Officer, effective August 14, 2026 (the “Effective Date”) and separate from the Company on October 25, 2026.” 8-K

  • Ten Holdings (XHLD) · Jul 24, 2026

    “On July 23, 2026, Mr. Yuji Ishida, a member of the Board of Directors (the “Board”) of the Company, notified the Board of his resignation as a member of the Board, including his role as member and chair of the Audit Committee of the Board, effective immediately.” 8-K

  • Microchip Technology (MCHP) · Jul 24, 2026

    “On July 23, 2026, Richard J. Simoncic, Chief Operating Officer of Microchip Technology Incorporated (the "Company"), notified the Company that he was resigning from the Company effective August 17, 2026 to become Chief Executive Officer of Menlo Microsystems, Inc., a private company headquartered in Irvine, California.” 8-K

  • Gorman Rupp (GRC) · Jul 24, 2026

    “On July 23, 2026, James C. Kerr, Executive Vice President and Chief Financial Officer, informed The Gorman-Rupp Company (the “Company” or “Gorman-Rupp”) of his decision to retire from the Company.” 8-K

  • Baycom (BCML) · Jul 24, 2026

    “On July 21, 2026, Syvia L. Magid notified the Boards of Directors of BayCom Corp (the “Company”) and its wholly owned subsidiary, United Business Bank (the “Bank”), of her decision to resign as a director of the Company and the Bank, effective July 22, 2026.” 8-K

  • FedEx (FDX) · Jul 24, 2026

    “On July 20, 2026, the Board of Directors (the “Board”) of FedEx Corporation (“FedEx” or the “Company”), upon the recommendation of the Compensation and Human Resources Committee of the Board (the “Compensation & HR Committee”), approved the Executive Severance Plan, which will govern all future separations between FedEx and its executive officers.” 8-K

  • Estée Lauder Companies (The) (EL) · Jul 24, 2026

    “On July 20, 2026, Jennifer Hyman, a member of the Board of Directors (the “Board”) of The Estée Lauder Companies Inc. (the “Company”), notified the Company that she will retire from the Board, effective November 16, 2026 (the day before the Company’s 2026 Annual Meeting of Stockholders).” 8-K

  • Pediatrix Medical Group (MD) · Jul 24, 2026

    “On July 21, 2026, Ms. Moore and PMG Services, Inc., a wholly-owned subsidiary of the Company (“PMG”), entered into a Separation Agreement pursuant to which Ms. Moore will serve in an advisory role to the Company until October 31, 2026 and transition from the Company effective as of such date.” 8-K

The company's own words, from the opening sentence of its Form 8-K (Item 5.02).

5% stakes filed (Schedules 13D and 13G)

Largest federal contract awards

See the record behind any of these

Each company page opens free with one real filing and the counts of the last 12 months. OQRO Pro adds the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.

Get OQRO ProOpen Crescent Biopharma free$9.99 a month, cancel anytime